Lab space race

Finding lab space for startups and independent researchers in Houston needs to be easier, according to this expert

Rentable lab space is hard to come by. Getty Images

Finding coworking space is getting easier and easier for startups, but the same can't be said for startups looking for lab space. If Houston wants to continue to grow and develop its innovation ecosystem — specifically within research and development in the health sciences industry — the city needs more opportunities for small lab space real estate.

A little history

Houston has increasingly become a magnet for innovative life science companies, seeking to benefit from the Texas Medical Center's cadre of connections and the city's deep talent pool. While cutting edge research and licensed technology has long been a part of the TMC institutions and Houston landscape, until 2016, independent lab users had few options to start and grow their companies.

In March of 2016, JLabs at TMCx opened its doors, offering 34,000 square feet of shared office space, 22 private labs and two shared lab spaces. University of Houston's Innovation Center, located in a repurposed Schlumberger campus, began operation in September of the same year, offering 16 private labs and two shared lab spaces.

These two alternatives are fit out with benches and other specialized equipment and price their space similar to a furnished coworking model. However, both facilities have a preference for certain users.

In the case of UH's space, its priority is to accommodate companies that are licensing and commercializing university technology. JLabs also has a curated tenant pool — drawn from the local and national companies that fit their specific profile. Sharing lab space is not a fit for every company — especially those that are regulated or prohibited from doing so. What appears to be an unmet need is affordable independent lab space for companies ready to launch from shared space.

Unique requirements

Aside from equipment that must be purchased and installed, lab users require more electrical power, plumbing, and air-conditioning than typically found in available suites in independent office parks. Second generation lab space under 2,000 square feet is extremely hard to find, and traditional landlords prefer a 5-year lease commitment.

While several new projects have been announced — and a new crop of landlords are trying to capitalize on the city's increased demand for specialized space — their pricing model is a better fit for established companies. From a user perspective, given the capital constraints of early stage life science companies, it is worth exploring the option to convert traditional warehouse space for lab use in exchange for a medium term commitment.

Buyer beware

Migrating from a full service lab to an independent suite does come with a warning, however, especially if a company is regulated and the condition of the space is subject to inspection. Lab tenants are well advised to factor in issues like the age of the air-conditioning units, whether a future backup power source is permitted, and the method for removal of medical waste. For firms that are in the pre-revenue stage, they should also be prepared to pay some amount of prepaid rent and the cost of customized alterations.

------

Julie King is president of NB Realty Partners. She has mentored and provided commercial real estate advice to technology, biotech, and early-stage companies for over 20 years.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted